Potential roles of ellagic acid on metabolic variables in diabetes mellitus : A systematic review
© 2022 John Wiley & Sons Australia, Ltd..
Diabetes mellitus is a widespread endocrine disorder globally. Due to its antioxidant and anti-inflammatory properties, ellagic acid has the potential to improve the metabolic effects of chronic non-communicable diseases. This systematic review summarizes current evidence about the potential effects of ellagic acid on metabolic variables in diabetes mellitus. A comprehensive systematic literature search was conducted in databases such as PubMed, Scopus, EMBASE, ProQuest and Google Scholar from inception until March 2022. All animal studies and clinical trials were eligible for inclusion. Studies using in vitro models or published in a non-English language were excluded. Of 1320 articles, 23 were selected for assessment, including 21 animal studies and two randomized controlled trial studies. Following ellagic acid administration, findings reported improvement in FBS, HbA1c, insulin (20, 8 and 12 studies, respectively), TG, TC, HDL-C (13, 10 and 5 studies, respectively), MDA, GSH, CAT, SOD (11, 6, 3 and 4 studies, respectively), and TNF-α and IL-6 (6 and 3 studies, respectively). In conclusion, ellagic acid may improve glycaemic indicators, dyslipidaemia, oxidative stress and inflammation in diabetes mellitus. However, further clinical trials are needed to explore the mechanisms more precisely and to observe the applied consequences.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:50 |
|---|---|
| Enthalten in: |
Clinical and experimental pharmacology & physiology - 50(2023), 2 vom: 08. Feb., Seite 121-131 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Maleki, Vahid [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.01.2023 Date Revised 25.02.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/1440-1681.13729 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347373429 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347373429 | ||
| 003 | DE-627 | ||
| 005 | 20231226033651.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/1440-1681.13729 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1157.xml |
| 035 | |a (DE-627)NLM347373429 | ||
| 035 | |a (NLM)36222179 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Maleki, Vahid |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Potential roles of ellagic acid on metabolic variables in diabetes mellitus |b A systematic review |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.01.2023 | ||
| 500 | |a Date Revised 25.02.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 John Wiley & Sons Australia, Ltd. | ||
| 520 | |a Diabetes mellitus is a widespread endocrine disorder globally. Due to its antioxidant and anti-inflammatory properties, ellagic acid has the potential to improve the metabolic effects of chronic non-communicable diseases. This systematic review summarizes current evidence about the potential effects of ellagic acid on metabolic variables in diabetes mellitus. A comprehensive systematic literature search was conducted in databases such as PubMed, Scopus, EMBASE, ProQuest and Google Scholar from inception until March 2022. All animal studies and clinical trials were eligible for inclusion. Studies using in vitro models or published in a non-English language were excluded. Of 1320 articles, 23 were selected for assessment, including 21 animal studies and two randomized controlled trial studies. Following ellagic acid administration, findings reported improvement in FBS, HbA1c, insulin (20, 8 and 12 studies, respectively), TG, TC, HDL-C (13, 10 and 5 studies, respectively), MDA, GSH, CAT, SOD (11, 6, 3 and 4 studies, respectively), and TNF-α and IL-6 (6 and 3 studies, respectively). In conclusion, ellagic acid may improve glycaemic indicators, dyslipidaemia, oxidative stress and inflammation in diabetes mellitus. However, further clinical trials are needed to explore the mechanisms more precisely and to observe the applied consequences | ||
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a diabetes mellitus | |
| 650 | 4 | |a dyslipidemia | |
| 650 | 4 | |a ellagic acid | |
| 650 | 4 | |a glycemic status | |
| 650 | 4 | |a inflammation | |
| 650 | 4 | |a oxidative stress | |
| 650 | 7 | |a Ellagic Acid |2 NLM | |
| 650 | 7 | |a 19YRN3ZS9P |2 NLM | |
| 650 | 7 | |a Antioxidants |2 NLM | |
| 650 | 7 | |a Blood Glucose |2 NLM | |
| 700 | 1 | |a Abbaszadeh, Sepideh |e verfasserin |4 aut | |
| 700 | 1 | |a Seyyed Shoura, Seyyed Morteza |e verfasserin |4 aut | |
| 700 | 1 | |a Sohrabnavi, Asma |e verfasserin |4 aut | |
| 700 | 1 | |a Sepandi, Mojtaba |e verfasserin |4 aut | |
| 700 | 1 | |a Taghdir, Maryam |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and experimental pharmacology & physiology |d 1974 |g 50(2023), 2 vom: 08. Feb., Seite 121-131 |w (DE-627)NLM000108138 |x 1440-1681 |7 nnns |
| 773 | 1 | 8 | |g volume:50 |g year:2023 |g number:2 |g day:08 |g month:02 |g pages:121-131 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/1440-1681.13729 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 50 |j 2023 |e 2 |b 08 |c 02 |h 121-131 | ||